Introduction

Patients follow-up
Patients underwent clinical follow-up to assess the relation between sFLC concentration at CLL diagnosis on primary endpoints such as time to first treatment (TFT), overall response rate (ORR) to therapy and overall survival (OS). Evaluation of responses to anticancer therapy was made based on criteria of response to the treatment according to the criteria of International Workshop on Chronic Lymphocytic Leukemia (IWCLL) [15] .
Blood preparation
Peripheral blood samples were collected into tubes without anticoagulant, and then within 2 hours centrifuged for 10 minutes at 1600 x g at room temperature (Eppendorf 5810R, Germany). The prepared sera were stored at -80 ° C until further analysis.
Assessment of sFLC concentration
The sFLC were measured using a latex-enhanced immunoassay (Freelite; The Binding Site, Birmingham, UK) on a Cobas Integra 400 plus analyzer (Roche Diagnostics, Mannheim, Germany). Normal ranges were 3.3-19.4 mg/l for κ sFLC, 5.7-26.3 mg/l for λ sFLC and 0.26-1.65 for κ/λ ratio (sFLCR). The analysis was performed according to the manufacturer's instructions. To further dissect the potential predictive value of sFLC, the κ and λ FLC concentrations were summed to produce a new variable, summed κ and λ. Based on literature data [11] the cut-off point was set at 66.6 mg/l. 
Statistical analysis
The obtained results were subjected to statistical analysis based on 
Results
sFLC and sFCLR values
The mean sFLC κ concentration in the study group was 48. 
Correlations between sFLCs, sFLCR and primary endpoints
The average follow-up time was 72.5 ± 25.2 months (min. 8 months,
max. 129 months). 10 patients died during the follow-up.
At the time of data analysis, 49% (n = 29) patients enrolled in the study completed the first-line therapy. Mean TFT was 18.5 ± 24.6 months (at least 0 months, max 85 months). The following treatment regimens were used in the study group: chlorambucil in combination with prednisone (n = 12), fludarabine in combination with cyclophosphamide +/-rituximab (n = 9), bendamustine +/-rituximab 
Discussion
Abnormalities in the secretion of sFLC have been previously reported in patients with B-cell NHL, including CLL [9] . Witzig et al. [16] analyzed the expression of sFLC in a population of 492 patients with newly diagnosed B and T-cell lymphomas. They showed that the expression of sFLC and abnormal sFLCR most often (79% of respondents, including 50% monoclonal, 29% polyclonal) were reported in the lymphoplasmacytic lymphoma (LPL) population, mantle cell lymphoma (68% of patients, 24% monoclonal; 44 % polyclonal), There are suggestions that analysis of CLL patients with sFLC assays may also provide additional information regarding outcome.
In our study, there was no significant correlation between sFLC κ and sFLCR concentration and parameters of the whole blood count, however, in the patients with elevated sFLC λ, the number of platelets was lower and the concentration of β-2 microglobulin was higher that might be associated with higher tumor burden.
Statistical analysis confirmed also a significantly higher sFLC κ On opposite, Yegin et al. [21] noted the relationship between abnormal sFLC and FLCR and LDH activity, hemoglobin concentration, platelet, leukocyte, and lymphocyte counts [21] . The relationship between overexpression of CD-38 antigen and increased sFLC concentration, might indicate that they are markers of excessive stimulation of B lymphocytes. The relationship between abnormal FLCR and ZAP-70, expression, cytogenetics aberrations, TFT in a multivariate model was demonstrated in a large group of 446 patients [11] .
We found no differences in sFLC level between the patients with adverse cytogenetic aberrations (del17p and/or del11q) and/or high ZAP-70 expression and the population with standard cytogenetic risk and/or low ZAP-70 expression. However, it should be noted that this assessment, could be unreliable due to the small size of the group.
Therefore, further research is needed in concerning this subject.
Our results suggest that higher sFLC κ expression in patients with unfavorable prognostic factors such as clinical stage according to Rai, β-2 microglobulin concentration, LDH activity and CD38
expression could be helpful in selecting the population of patients with progressive form of the disease.
An important element in the assessment of the prognostic value of the studied factor is an attempt to assess its impact on the primary endpoints. Literature data confirmed the relationship between sFLC concentration and FLCR disorders and both OS and TFT. Pratt et al. [18] showed that high concentration of sFLC was an independent factor, associated with increased mortality in the studied population, regardless of the cause of death. Also, if only CLL-related deaths were taken into account, the elevated concentration of sFLC was associated with a shorter OS. TFT was statistically significantly longer in the group of patients with lower sFLC levels [18] . Also, Morabito et al. [11] unambiguously confirmed the relationship between abnormal FLC κ and λ concentration and TFT. These studies are in line with the results of Maurer et al. [22] who found that sFLC and FLCR can be considered as independent prognostic factors and translate into OS and TFT, regardless of whether secretion of sFLC was polyclonal or monoclonal. In this study, higher sFLC levels were found in older patients, with elevated creatinine levels that could also contribute to shorter OS [22] .
Our own research does not confirm the relationship between sFLC, summed κ and λ and sFCLR and primary endpoints such as OS, TFT and ORR. However, it should be emphasized that CLL is an extremely heterogeneous disease and very often at the time of the diagnosis does not show clinical symptoms, and in the case of patients who do not perform regular check-ups, the diagnosis can be made even a few years after the first disturbances in peripheral blood morphology. The sFLC and FLCR determinations were made at the time of the diagnosis, therefore a meaningful determination of OS and TFT length in this group of patients is difficult. Also, the ORR assessment in such a small group of patients could not be reliable, especially considering the number of different treatment regimens that are used in everyday clinical practice and the necessity to reduce doses of cytostatics in older patients with numerous comorbidities.
It would be interesting to evaluate predictive value of sFLC in larger group of patients treated with new agents, such as BCR or Bcl-2 inhibitors.
Despite the fact that many prognostic factors have been identified so far, their role in prognosing the course of the disease and anticancer therapy is very often still unclear. The introduction of new molecular and cytogenetic markers to everyday clinical practice is very often impossible due to the high cost-effectiveness and the need to have adequate laboratory facilities. That is why it is important to look for new, cheaper markers that will allow to optimize the treatment choice [23] . Taking into account the results of our research and the literature on the subject presented above, it can be concluded that the evaluation of sFLC expression, summed κ and λ levels and sFLCR disorders in patients with CLL may be an important element that supplements the diagnostic procedure. It would be interesting to assess the predictive value of these parameters in relation to ORR, carried out in a larger and more homogeneous group of patients.
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